This product is a semi-synthetic 14-membered macrolide antibiotic. The antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, and stronger than erythromycin against Legionella pneumophila. The antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.

No specific pharmacological effects mentioned

Fenofibrate can reduce serum cholesterol by 20-25% and triglycerides by 40-50%. It improves the distribution of cholesterol in plasma by reducing low-density atherogenic components (VLDL and LDL) and improving the total cholesterol/HDL cholesterol ratio. In addition, fenofibrate has a pro-uric acid effect, which can reduce plasma uric acid by an average of 25% and improve the apoAⅠ/apoB ratio. It also has an anti-platelet aggregation effect, and increases fat degradation and triglyceride clearance in plasma by activating PPARα (peroxisome proliferator-activated receptor α).